Eyewire+FDA Approves Outlook Therapeutics’ Lytenava as First Ophthalmic Bevacizumab for Wet AMD

📋 Regulatory Action / Label Change

Lytenava becomes the first FDA-approved ophthalmic bevacizumab for wet AMD. Outlook says the formulation was developed specifically for intravitreal administration.

Professional Impact

• Approval gives retina clinicians an FDA-reviewed alternative to repackaged intravenous bevacizumab for ocular use.
• Outlook cites validated manufacturing, clinical data, approved labeling, and ongoing regulatory oversight.
• The company expects US availability before year-end with reimbursement and patient support programs.

Action Items

• Review formulary, payer, and acquisition pathways as launch details become available.
• Monitor patient assistance and reimbursement updates before availability.
• Evaluate where FDA-approved bevacizumab may fit within wet AMD discussions.